Legal Cannabis and CBD Markets Grow in the United States

NEW YORK, May 16, 2017 /PRNewswire/ --

According to a research by New Frontier Data, the legal cannabis market was worth an estimated $7.2 billion in 2016. The medical market is projected to grow at 13% CAGR through 2025, growing from $4.7 billion in 2016 to an estimated $13.3 billion in 2020. During the same period, adult-use sales are projected to grow at a 25% CAGR, from $2.6 billion to $11.2 billion. The report indicates the projections are based on assumptions that no other states will legalize cannabis use throughout the forecast period. As expected from a new growing market, the legal cannabis industry is projected to become a major job creating merchantry. "These numbers confirm that cannabis is a major economic driver and job creation engine for the U.S. economy," said Giadha Aguirre De Carcer, Founder and CEO of New Frontier Data. ChineseInvestors.com, Inc. (OTC: CIIX), Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP), Eco Science Solutions, Inc. (OTC: ESSI), General Cannabis Corporation (OTC: CANN)

One major component of the legal cannabis industry is the CBD market. A report by the The Hemp Business Journal estimates that the CBD market will grow to a $2.1 billion market in consumer sales by 2020 with $450 million of those sales coming from hemp-based sources. In 2015, the market for consumer sales of hemp-derived CBD products were $90 million, plus another $112 million in marijuana-derived CBD products, sold through dispensaries - bringing a total CBD market to $202 million last year. That's a 700% increase from 2016.

ChineseInvestors.com, Inc. (OTCQB: CIIX) announced on May 2nd that it has appointed Summer (XiangYang) Yun as Chief Executive Officer (CEO) of its wholly-owned foreign entity, CBD Biotechnology Co., Ltd. XiBiDi Biotech's primary focus is online, retail and direct sales of hemp-based health products in China. Yun's initial focus will be the launch of 'CBD Magic Hemp Series' cosmetics line. He will also spearhead the Company's plan to import natural dietary supplements created using advanced extracting and purifying technologies into China. Yun is a marketing and branding executive with over 25 years of experience. Yun will report directly to CIIX's CEO Warren Wang.

"I am honored to be named as CEO of CBD Biotech," says Yun. "For over 5,000 years, hemp has been cultivated and used in over 25,000 products worldwide. CIIX has a unique opportunity to become one of the first companies to offer CBD-based skin care products in China online and through established retail and direct selling channels. Through the introduction of Magic CBD Series cosmetics to China, I hope to educate consumers regarding hemp's many benefits."

The CBD Magic Hemp Series line will include cleansers, moisturizing lotions and anti-aging products created using supercritical CO2 extraction technology. CBD Biotech also plans to launch a series of oral spray vitamins and supplements that can be used for relaxation, pain relief and sleep, among other things. Yun will oversee marketing and sales of these products in China, and utilizing his branding and marketing expertise, he will work to grow the CBD Biotech brand.

"I believe Yun is the perfect candidate to oversee CBD Biotech's operations. I am confident in his ability to introduce this revolutionary CBD-based skin care line to China and create and generate substantial revenue for CIIX," says Wang.

Zynerba Pharmaceuticals Inc. (NASDAQ: ZYNE) dedicates to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with high unmet medical needs. On March 13, 2017, the company announced that it has completed enrollment in the Phase 2 STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) clinical trial evaluating ZYN002 cannabidiol (CBD) gel in adult epilepsy patients with refractory focal seizures. The Company also announced that enrollment has completed in the Phase 2 STOP (Synthetic Transdermal Cannabidiol for the Treatment of Knee Pain due to Osteoarthritis) clinical trial evaluating ZYN002 CBD gel for the treatment of osteoarthritis.

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) recently announced that subject enrollment is complete in its Phase 2 clinical study of anabasum (formerly known as JBT-101) for the treatment of skin-predominant dermatomyositis. The Company expects topline results from this study to be available in the fourth quarter of 2017. Anabasum is a first-in-class, synthetic oral endocannabinoid-mimetic drug that preferentially binds to the cannabinoid receptor type 2 (CB2) receptor expressed on activated immune cells and fibroblasts. CB2 activation triggers endogenous pathways that resolve inflammation and halt fibrosis.

Eco Science Solutions, Inc. (OTCQB: ESSI) is a technology-focused company targeting the health, wellness and alternative medicine industry. Recently, the company announced that it has signed a Sponsorship, Content Development and Licensing agreement with Roaring Lion Tours, Inc. to develop unique educational content that brings awareness and education to the alternative medicine category. Roaring Lion Tour develops inspirational and educational content that further promotes the benefits of medical marijuana. "There is a continuing need to bring awareness to the benefits of medical marijuana as a key category in the alternative medical health industry," stated Jeff Taylor, Chief Executive Officer of Eco Science Solutions.

General Cannabis Corporation (OTCQB: CANN) is the comprehensive resource for the highest quality service providers available to the regulated Cannabis Industry. Recently, the company announced financial results for the quarter ended March 31, 2017. In the first quarter, the company reported a 4% increase in total revenues when compared to the quarter ended March 31, 2016. During the first quarter of 2017, the company's Operations segment, Next Big Crop, increased revenues by 119% over the first quarter of 2016. "Next Big Crop, our Operations segment, had record revenues in the first quarter of 2017," said Robert Frichtel, Chief Executive Officer of General Cannabis.

Please Sign Up Now at http://www.FinancialBuzz.com to Receive Alerts on Trending Financial News from all these companies. 'The Latest Buzz in Financial News'

Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia

Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz

Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz

Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/

About FinancialBuzz.com

FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the "Site") is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions as we purely incorporate public market research along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. We also do not include any personal opinions or commentary. For this release, FinancialBuzz.com expects to be compensated three thousand dollars for financial news dissemination and pr services by chineseInvestors.com inc. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com has signed a two year agreement with chineseinvestors.com inc. for one hundred thousand restricted common shares for continued financial news dissemination and pr services. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on the Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use. Please visit: http://www.financialbuzz.com

For further information:
Media Contact:
[email protected]
+1-877-601-1879

Url: http://www.FinancialBuzz.com

SOURCE FinancialBuzz.com